Angiotensin II vs. Vasopressin in Septic Shock

PHASE4WithdrawnINTERVENTIONAL
0
Timeline

Start Date

January 3, 2022

Primary Completion Date

November 30, 2022

Study Completion Date

November 30, 2022

Conditions
Septic Shock
Interventions
DRUG

Angiotensin II

Angiotensin II (Giapreza) is a pharmacologic version of a naturally occurring hormone of the same name, peptide hormone of the renin-angiotensin-aldosterone system (RAAS), that was FDA-approved in 2017 as a vasoconstrictive agent in the treatment of vasodilatory shock.

DRUG

Vasopressin

Vasopressin (Vasostrict) is a pharmacologic version of a naturally occurring peptide hormone that serves as a vasoconstrictive agent in the treatment of vasodilatory shock.

Trial Locations (1)

87106

University of New Mexico Health Sciences Center, Albuquerque

Sponsors
All Listed Sponsors
collaborator

La Jolla Pharmaceutical Company

INDUSTRY

collaborator

National Center for Advancing Translational Sciences (NCATS)

NIH

lead

University of New Mexico

OTHER

NCT05193370 - Angiotensin II vs. Vasopressin in Septic Shock | Biotech Hunter | Biotech Hunter